AMR: Germany set to invest €39m into CARB-XGlobal antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership. more ➔
AstraZeneca partners with Seres TherapeuticsUnder a three-year agreement, British pharma giant AstraZeneca plc pays €20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response … more ➔
AMR: Snipr Biome Aps raises €43m to programme pathogens for deathCopenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) … more ➔
Small-molecule acts as broad-band influenza entry blockerResearchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes. more ➔
Seventure starts second microbiome-focussed fundSeventure Partners has announced the first close of its second microbiome fund designed to put €200m in 20 companies developing microbiome-based health solutions. more ➔
Numab AG bags CHF70m in licencing dealSwiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc. more ➔
Biogen bags UK company Nightstar for US$877mBiogen has strengthened its portfolio with Nightstar Therapeutics, a British gene therapy specialist for rare inherited eye disorders. more ➔
EMA approves eight meds for marketThe EMA’s human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authori … more ➔
Genfit set to raise $100m in Nasdaq IPOFrench Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US. more ➔
Targeting NFkappaB protects tendons from injuryResearchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation. more ➔
